Looking at lithium: molecular moods and complex behaviour - PubMed (original) (raw)
Review
Looking at lithium: molecular moods and complex behaviour
Jean-Martin Beaulieu et al. Mol Interv. 2008 Oct.
Abstract
Lithium and other mood-stabilizing drugs are used for the management of bipolar mood disorders and, to a lesser extent, for augmentation of other psychoactive drugs. Lithium also has neuroprotective properties that may be useful for treatment of neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis. Over the years, lithium has been shown to inhibit inositol monophosphatases and glycogen synthase kinase 3, but the relevance of such enzyme inhibition to the therapeutic effects of lithium has remained difficult to assess. Here, we provide an overview of recent advances in the identification of molecular mechanisms involved in the regulation of behavior by lithium. We also highlight recent findings suggesting that lithium could exert some of its behavioral effects by acting on a dopamine receptor regulated signaling complex composed of Akt, protein phosphatase 2A, and the multifunctional protein scaffold beta-arrestin 2.
Similar articles
- A beta-arrestin 2 signaling complex mediates lithium action on behavior.
Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG. Beaulieu JM, et al. Cell. 2008 Jan 11;132(1):125-36. doi: 10.1016/j.cell.2007.11.041. Cell. 2008. PMID: 18191226 - Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice.
O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, Klein PS. O'Brien WT, et al. J Clin Invest. 2011 Sep;121(9):3756-62. doi: 10.1172/JCI45194. Epub 2011 Aug 8. J Clin Invest. 2011. PMID: 21821916 Free PMC article. - Akt/GSK3 signaling in the action of psychotropic drugs.
Beaulieu JM, Gainetdinov RR, Caron MG. Beaulieu JM, et al. Annu Rev Pharmacol Toxicol. 2009;49:327-47. doi: 10.1146/annurev.pharmtox.011008.145634. Annu Rev Pharmacol Toxicol. 2009. PMID: 18928402 Review. - The Akt-GSK-3 signaling cascade in the actions of dopamine.
Beaulieu JM, Gainetdinov RR, Caron MG. Beaulieu JM, et al. Trends Pharmacol Sci. 2007 Apr;28(4):166-72. doi: 10.1016/j.tips.2007.02.006. Epub 2007 Mar 8. Trends Pharmacol Sci. 2007. PMID: 17349698 Review. - Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
Urs NM, Snyder JC, Jacobsen JP, Peterson SM, Caron MG. Urs NM, et al. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20732-7. doi: 10.1073/pnas.1215489109. Epub 2012 Nov 27. Proc Natl Acad Sci U S A. 2012. PMID: 23188793 Free PMC article.
Cited by
- Lithium compartmentation in brain by 7Li MRS: effect of total lithium concentration.
Komoroski RA, Lindquist DM, Pearce JM. Komoroski RA, et al. NMR Biomed. 2013 Sep;26(9):1152-7. doi: 10.1002/nbm.2929. Epub 2013 Feb 12. NMR Biomed. 2013. PMID: 23401319 Free PMC article. - Mood and behavior regulation: interaction of lithium and dopaminergic system.
Mohamadian M, Fallah H, Ghofrani-Jahromi Z, Rahimi-Danesh M, Shokouhi Qare Saadlou MS, Vaseghi S. Mohamadian M, et al. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1339-1359. doi: 10.1007/s00210-023-02437-1. Epub 2023 Feb 27. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36843130 Review. - Inhibition of GSK3 by lithium, from single molecules to signaling networks.
Freland L, Beaulieu JM. Freland L, et al. Front Mol Neurosci. 2012 Feb 20;5:14. doi: 10.3389/fnmol.2012.00014. eCollection 2012 Jan 27. Front Mol Neurosci. 2012. PMID: 22363263 Free PMC article. - Ezrin-radixin-moesin proteins are regulated by Akt-GSK3β signaling in the rat nucleus accumbens core.
Kim WY, Cai WT, Jang JK, Kim JH. Kim WY, et al. Korean J Physiol Pharmacol. 2020 Jan;24(1):121-126. doi: 10.4196/kjpp.2020.24.1.121. Epub 2020 Dec 20. Korean J Physiol Pharmacol. 2020. PMID: 31908581 Free PMC article. - Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator.
Parekh PK, Sidor MM, Gillman A, Becker-Krail D, Bettelini L, Arban R, Alvaro GS, Zambello E, Mutinelli C, Huang Y, Large CH, McClung CA. Parekh PK, et al. Neuropsychopharmacology. 2018 Jan;43(2):435-444. doi: 10.1038/npp.2017.155. Epub 2017 Aug 31. Neuropsychopharmacology. 2018. PMID: 28857068 Free PMC article.